GLP-1 Options for Zimbabweans

GLP-1 receptor agonists have transformed weight management globally, and Zimbabweans now have access to these medications through established channels. Understanding your options helps you make informed decisions with your healthcare provider.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a hormone your intestines release after eating. This hormone tells your brain you are full, slows stomach emptying, and helps regulate blood sugar. GLP-1 medications mimic this natural hormone but last much longer in your body.

Unlike appetite suppressants that worked through the nervous system (and often caused jitteriness or heart problems), GLP-1 medications work through the same pathways your body already uses. This makes them both effective and well-tolerated for most people.

Semaglutide: The Established Option

Semaglutide has been available for weight management since 2021. Originally developed for diabetes management, it was later approved specifically for weight loss. Compounded versions contain semaglutide, an FDA-approved active ingredient, at accessible price points.

How Semaglutide Works

After injection, semaglutide circulates in your bloodstream for about a week. During this time, it continuously activates GLP-1 receptors in your brain's appetite centre, reducing hunger and food-seeking behaviour. It also slows gastric emptying, meaning food stays in your stomach longer, extending the feeling of fullness after meals.

Expected Results

Clinical studies showed participants lost a clinically meaningful amount of body weight over 68 weeks. For someone weighing 90kg, this could translate to substantial weight loss. Results varied—some lost more, others less—depending on adherence to dietary recommendations and individual metabolism.

Dosing Schedule

Treatment begins with a low dose (0.25mg weekly) for four weeks to allow your body to adjust. The dose increases gradually over 16-20 weeks until reaching the maintenance level. This slow titration minimises side effects and improves long-term tolerance.

Tirzepatide: The Dual-Action Option

Tirzepatide represents the newest class of weight loss medications. Marketed as Mounjaro for diabetes and Zepbound for weight loss, it activates two hormone receptors instead of one.

The Dual Mechanism

Beyond GLP-1, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP plays a role in fat metabolism and insulin response. By targeting both pathways, tirzepatide produces stronger appetite suppression and greater metabolic effects than GLP-1-only medications.

Superior Weight Loss Results

In published clinical research, tirzepatide users lost significantly more body weight than those on semaglutide alone. Weight loss results were unprecedented for any non-surgical intervention. A 90kg person could expect meaningful and sustained weight reduction.

Dosing Approach

Like semaglutide, tirzepatide starts low (2.5mg weekly) and increases every four weeks. Most people reach their optimal dose between 10-15mg weekly, though some respond well to lower doses.

Comparing Your Options

Both medications require weekly subcutaneous injection using a small needle similar to those used by diabetics. Most people inject in the abdomen, thigh, or upper arm, rotating sites each week.

Semaglutide advantages: Longer track record means more safety data. Some people prefer starting with the "original" before trying newer options. Generally requires less refrigeration vigilance once opened.

Tirzepatide advantages: Greater average weight loss. May work better for people who have tried semaglutide with limited success. Some users report fewer gastrointestinal side effects.

Who Should Consider GLP-1 Medications?

These medications suit adults with a BMI of 30 or higher (obesity), or those with a BMI of 27 or higher (overweight) who also have weight-related health conditions like high blood pressure, type 2 diabetes, or elevated cholesterol.

Candidates should have previously attempted weight loss through diet and exercise without achieving lasting results. GLP-1 medications are not shortcuts—they work alongside healthy eating and physical activity, not instead of them.

Who Should Avoid These Medications?

Certain conditions rule out GLP-1 use. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not take these medications. Pregnant or breastfeeding women must also avoid them.

Those with severe gastrointestinal conditions like gastroparesis or inflammatory bowel disease may experience worsened symptoms. A history of pancreatitis requires careful evaluation before starting treatment.

Managing Side Effects

Most people experience some gastrointestinal symptoms initially—nausea, occasional vomiting, diarrhoea, or constipation. These typically peak during dose increases and improve within two to four weeks at each new dose level.

Eating smaller meals, avoiding fatty foods, and staying hydrated helps manage nausea. Ginger tea, common in Zimbabwean households, provides natural relief for stomach upset. If symptoms persist or worsen, dose adjustments usually resolve the issue.

Storage Requirements in Zimbabwe

GLP-1 medications require refrigeration between 2-8°C before first use. Given Zimbabwe's warm climate and occasional power interruptions, proper storage matters. Unopened medication can tolerate brief temperature excursions, but prolonged heat exposure degrades the active ingredient.

Once opened, pens can be stored at room temperature (below 30°C) for 28-56 days depending on the specific product. Keep them away from direct sunlight and never freeze. A cooler bag with ice packs helps during travel or load shedding.

Getting Started in Zimbabwe

Accessing GLP-1 medications in Zimbabwe requires working with a medical provider who can assess your suitability, prescribe appropriately, and monitor your progress. Remote consultations have made this process more accessible for people outside Harare and Bulawayo.